Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection.
The immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin, filamentous haemoagglutinin and pertactin was studied in 12 children [median age: 45 (6-107) months] with perinatal human immunodeficiency virus-type 1 (HIV-1) infection. Antibody response to all antigens was observed in six cases and another children 3 reacted to two or one antigen(s), but titres were lower than those from healthy controls. Antibody titre fold-rise correlated with preimmunization CD4-positive cell counts. Significant titres were still detectable 4 months after the third dose. The acellular vaccine is immunogenic in a portion of children with perinatal HIV-1 infection but early vaccination might be more effective, taking advantage of still adequate CD4-positive cell numbers.
de Martino
M
M
Department of Medicine, University of Chieti, Italy.
Podda
A
A
Galli
L
L
Sinangil
F
F
Mannelli
F
F
Rossi
M E
ME
Vierucci
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D016014:Linear Models; D008297:Male; D010567:Pertussis Vaccine / Q000276:immunology* / Q000302:isolation & purification; D010865:Pilot Projects
D000907:Antibodies, Bacterial; D010567:Pertussis Vaccine